Lance Miller to Female
This is a "connection" page, showing publications Lance Miller has written about Female.
Connection Strength
0.708
-
Moaven O, Su J, Jin G, Votanopoulos KI, Shen P, Mangieri C, O'Neill SS, Perry KC, Levine EA, Miller LD. Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. Ann Surg Oncol. 2020 Dec; 27(13):5016-5023.
Score: 0.051
-
Routh ED, Pullikuth AK, Jin G, Chifman J, Chou JW, D'Agostino RB, Seino KI, Wada H, Print CG, Zhang W, Lu Y, Miller LD. Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Front Immunol. 2020; 11:57.
Score: 0.050
-
Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol Res. 2016 07; 4(7):600-10.
Score: 0.038
-
Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD. Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. J Am Coll Surg. 2016 Apr; 222(4):493-503.
Score: 0.037
-
Bedognetti D, Hendrickx W, Marincola FM, Miller LD. Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol. 2015 Nov; 27(6):433-44.
Score: 0.037
-
Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013 Apr 29; 14(4):R34.
Score: 0.031
-
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R, Torti SV, Torti FM. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6728-37.
Score: 0.028
-
Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET, Karuturi KM, Lim B, Miller LD. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009 Aug; 119(8):2171-83.
Score: 0.024
-
Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006 Nov 01; 66(21):10292-301.
Score: 0.020
-
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005 Sep 20; 102(38):13550-5.
Score: 0.018
-
Su J, Jin G, Votanopoulos KI, Craddock L, Shen P, Chou JW, Qasem S, O'Neill SS, Perry KC, Miller LD, Levine EA. Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2020 May; 27(5):1439-1447.
Score: 0.012
-
Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385.
Score: 0.012
-
Salvador Moreno N, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Res. 2019 04 08; 47(6):2703-2715.
Score: 0.012
-
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar; 34(1):90-97.
Score: 0.012
-
Dotson T, Bellinger C, Su J, Hansen K, Parks GE, Cappellari JO, Craddock L, Clark H, Howard C, Petty WJ, Prakash B, Watabe K, Chan M, Hovda J, Miller LD, Ruiz J. Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). Lung Cancer. 2019 01; 127:6-11.
Score: 0.011
-
Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct; 60(10):1043-1051.
Score: 0.011
-
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.
Score: 0.011
-
Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. Oncologist. 2018 04; 23(4):481-488.
Score: 0.011
-
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.
Score: 0.010
-
Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller LD, Dyment N, Torti FM, Torti SV. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017 07 20; 36(29):4089-4099.
Score: 0.010
-
Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. J Am Soc Nephrol. 2017 Apr; 28(4):1093-1105.
Score: 0.010
-
Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. Clin Breast Cancer. 2017 Apr; 17(2):139-153.
Score: 0.010
-
Dewi FN, Wood CE, Willson CJ, Register TC, Lees CJ, Howard TD, Huang Z, Murphy SK, Tooze JA, Chou JW, Miller LD, Cline JM. Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques. Cancer Prev Res (Phila). 2016 05; 9(5):385-95.
Score: 0.010
-
Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G. Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. J Mol Cell Biol. 2016 06; 8(3):232-43.
Score: 0.009
-
Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK. ERRa Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1421-31.
Score: 0.009
-
Song Q, Wang H, Bao J, Pullikuth AK, Li KC, Miller LD, Zhou X. Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Sci Rep. 2015 Aug 10; 5:12981.
Score: 0.009
-
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol. 2015 Sep; 124(3):447-53.
Score: 0.009
-
Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. . 2015; 16(5):678-83.
Score: 0.009
-
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.
Score: 0.009
-
Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP, Tergaonkar V. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest. 2014 Sep; 124(9):3807-24.
Score: 0.008
-
Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014 Sep; 119(2):429-35.
Score: 0.008
-
Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB, Torti FM, Torti SV. IRP2 regulates breast tumor growth. Cancer Res. 2014 Jan 15; 74(2):497-507.
Score: 0.008
-
Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013 Nov; 183(5):1645-1653.
Score: 0.008
-
Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 2013 Aug 29; 32(35):4120-9.
Score: 0.007
-
Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 2012 May 23; 14(3):R85.
Score: 0.007
-
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. . 2012 Jul; 11(7):1488-99.
Score: 0.007
-
Prat A, Parker JS, Fan C, Cheang MCU, Miller LD, Bergh J, Chia SKL, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012 Nov; 23(11):2866-2873.
Score: 0.007
-
Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G. Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol. 2012 May; 180(5):2120-33.
Score: 0.007
-
Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012 Jan 18; 104(2):133-46.
Score: 0.007
-
Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, Wan M, Giri B, Lei M, Nagamine Y, Vaughn JP, Akman SA, Sui G. Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Res. 2012 Feb; 40(3):1033-49.
Score: 0.007
-
Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med. 2011 Aug; 3(8):451-64.
Score: 0.007
-
Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Régnard JF, Lim D, Koong HN, Agasthian T, Miller LD, Lim E, Camilleri-Broët S, Tan P. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res. 2011 Jun 01; 17(11):3542-50.
Score: 0.007
-
Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010 Dec; 12(12):1041-53.
Score: 0.007
-
Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB, Miller LD, Torti FM, Torti SV. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):737-46.
Score: 0.007
-
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. . 2010 Dec; 9(12):3186-99.
Score: 0.007
-
Alifano M, Souazé F, Dupouy S, Camilleri-Broët S, Younes M, Ahmed-Zaïd SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, Broët P, Miller LD, Gespach C, Regnard JF, Forgez P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010 Sep 01; 16(17):4401-10.
Score: 0.006
-
Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010 Aug 04; 2(43):43ra56.
Score: 0.006
-
Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010 Jun 03; 29(22):3228-40.
Score: 0.006
-
Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A. 2009 Aug 11; 106(32):13493-8.
Score: 0.006
-
Cheung AK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, Liu ET, Shao JY, Kou CW, Chua D, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res. 2008 Oct 01; 68(19):8137-45.
Score: 0.006
-
Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, Nakamura Y, Qi RZ, Miller LD, Liu ET, Wang LD, Li JL, Law S, Tsao SW, Lung ML. Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 2008 Feb 01; 122(3):587-94.
Score: 0.005
-
Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 2007 Jun; 3(6):e87.
Score: 0.005
-
Lin CY, Ström A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, Liu ET. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 2007; 9(2):R25.
Score: 0.005
-
Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006 Jul 15; 66(14):7334-40.
Score: 0.005
-
Hall P, Ploner A, Bjöhle J, Huang F, Lin CY, Liu ET, Miller LD, Nordgren H, Pawitan Y, Shaw P, Skoog L, Smeds J, Wedrén S, Ohd J, Bergh J. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006 Jun 30; 4:16.
Score: 0.005
-
Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002 Jul 01; 62(13):3581-6.
Score: 0.004